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Abstract
Background: Development of the hematopoietic and endothelial lineages derives from a common mesodermal precursor,
the Flk1
+ hemangioblast. However, the signaling pathways that regulate the development of hematopoietic and
endothelial cells from this common progenitor cell remains incompletely understood. Using mouse models with a
conditional Spry1 transgene, and a Spry1 knockout mouse, we investigated the role of Spry1 in the development of the
endothelial and hematopoietic lineages during development.
Methodology/Principal Findings: Quantitative RT-PCR analysis demonstrates that Spry1, Spry2, and Spry4 are expressed in
Flk1
+ hemangioblasts in vivo, and decline significantly in c-Kit
+ and CD41
+ hematopoietic progenitors, while expression is
maintained in developing endothelial cells. Tie2-Cre-mediated over-expression of Spry1 results in embryonic lethality. At
E9.5 Spry1;Tie2-Cre embryos show near normal endothelial cell development and vessel patterning but have reduced
hematopoiesis. FACS analysis shows a reduction of primitive hematopoietic progenitors and erythroblastic cells in
Spry1;Tie2-Cre embryos compared to controls. Colony forming assays confirm the hematopoietic defects in Spry1;Tie2-Cre
transgenic embryos. Immunostaining shows a significant reduction of CD41 or CD71 and dpERK co-stained cells in
Spry1;Tie2-Cre embryos compared to controls, whereas the number of VEC
+ and dpERK co-stained cells is comparable.
Compared to controls, Spry1;Tie2-Cre embryos also show a decrease in proliferation and an increase in apoptosis.
Furthermore, loss of Spry1 results in an increase of CD41
+ and CD71
+ cells at E9.5 compared with controls.
Conclusions/Significance: These data indicate that primitive hematopoietic cells derive from Tie2-expressing
hemangioblasts and that Spry1 over expression inhibits primitive hematopoietic progenitor and erythroblastic cell
development and expansion while having no obvious effect on endothelial cell development.
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Introduction
Primitive hematopoietic cells (HCs) arise in the yolk sac from
mesoderm-derived cells called blood islands (Bls) [1]. The
possibility of a common progenitor for endothelial cells (ECs)
and HCs, termed the hemangioblast, has been proposed based on
the observation that ECs and HCs emerge from BIs in proximity
and at a similar time during embryonic development. Studies in
embryonic stem (ES) cells indicate that blast colony-forming cells
(BL-CFU) lead to both HCs and ECs in vitro [2,3]. An alternative
to this bi-potential common precursor theory shows the first
hematopoietic cells emerging from phenotypically differentiated
endothelial cells that have hematopoietic potential (i.e. hemogenic
endothelium) [4]. Fate mapping reveals that hematopoietic cells
originate from VE-Cadherin (VEC) positive endothelial cells [5],
suggesting that a subset of definitive hematopoietic cells originate
directly from hemogenic endothelial cells. Recently, in vivo time-
lapse imaging of the dorsal aortic floor of mouse and zebrafish
provide direct evidence that hematopoietic cells emerge from
aortic endothelium [6,7,8]. Furthermore, the hemangioblast
generates hematopoietic cells through a hemogenic endothelium
stage and thus provides a link between these two hypotheses [9].
The control of the formation of the hemangioblast and
subsequent formation of hematopoietic and endothelial cells from
a common progenitor remains unclear. Many growth factors and
cytokines regulate hemangioblast formation, and subsequent
hematopoietic and angiogenic differentiation [10]. Studies on
embryonic stem cells show that fibroblast growth factor-2 (FGF2)
and activin A induce the differentiation of mesodermal precursors
to a hemangioblastic fate. However, the role of FGF and fibroblast
growth factor receptor (FGFR) signaling on hematopoietic and
endothelial cell differentiation is still controversial. Loss of FGFR1
function studies in murine embryonic stem cells showed that
FGFR1 signaling is required for hematopoietic but not endothelial
cell development [11]. In contrast, in the chick, high FGF activity
inhibits primitive hematopoiesis and promotes an endothelial cell
fate, whereas inhibition of FGFR activity leads to ectopic blood
formation and down-regulation of endothelial markers [12].
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cell growth factor (VEGF), is a marker for lateral plate
mesodermal and the earliest differentiation marker for endothelial
and hematopoietic cells. VEGF/Flk1 signaling mediates prolifer-
ation, migration, and differentiation. Disruption of Flk1 results in
embryonic lethality between E8.5 to E9.5 with an absence of blood
islands at E7.5 and no organized blood vessels in vivo [13].
However, Flk12/2 ES cells can differentiate into both lineages in
vitro [14], indicating that Flk-1 is required for the migration of
progenitors into the proper microenvironment during embryo-
genesis. In addition, VEGF is also required for the production of
fully committed hematopoietic progenitors. Heterozygous inacti-
vation of the VEGF gene results in impaired development of the
vascular and hematopoietic systems [15,16]. In the chicken, a high
concentration of VEGF inhibits the differentiation of hematopoi-
etic progenitor cells (HPCs) from VEGFR2
+ cells [17]. These data
indicate that precise regulation of FGFR and VEGFR signaling is
necessary for proper hemangioblast formation, migration and
subsequent hematopoietic and endothelial development.
Sproutys (Sprys) were identified as feedback regulators that
restrain receptor tyrosine kinase (RTK) signaling intensity and
duration [18,19]. Over-expression of Spry4 by adenoviral infection
of mouse embryos inhibited angiogenesis in vivo [20]. Compound
knockout of the Spry2 and Spry4 genes in mice leads to
cardiovascular and other defects and Spry42/2 mice have
accelerated angiogenesis in response to injury [21]. Morpholino
oligonucleotide mediated knock down of Spry4 in zebrafish leads to
hematopoietic defects [22]. However, the roles of Sprys in early
endothelial development and hematopoiesis have not been
addressed in mammals. In the present study, we found that Sprys
are expressed in Flk1
+ hemangioblasts and continually expressed in
developing endothelial cells, however expression is decreased in
hematopoietic c-Kit
+ and CD41
+ cells. Because Tie2 is expressed in
Flk1
+ hemangioblasts, beginning at E7.5, we used Tie2-Cre to
generate conditional Spry1 transgenic mice in this study. Over-
expression of Spry1 in Tie2-Cre expressing cells results in
embryonic lethality between E10.5 to E11. Further characterization
of Spry1;Tie2-Cre transgenic embryos showed a severe reduction in
primitive hematopoietic progenitor and erythroblastic cells, but had
normal endothelial cell formation at E9.5. In contrast, loss of Spry1
leads to an increase in CD71
+ progenitor cells at E9.5, although this
is not a fully penetrant phenotype. Furthermore, over-expression of
Spry1 increases apoptosis and decreases cell proliferation and is
associated with decreased pERK in CD41
+cells. Together, our
results indicate a decrease of Spry1 expression during hemangio-
blast committing to hematopoietic progenitors is necessary for
hematopoieticcelldevelopment and expansion,whereasendothelial
cell development is relatively unaffected.
Results
The expression of Sprys changes with the stage of
hematopoietic cell differentiation
Although Spry genes are expressed developmentally in a variety
of mouse tissues, endogenous expression in the hematopoietic and
endothelial cell precursors has not been characterized. Flk1
+
mesodermal cells give rise to the hemangioblast in early
embryogenesis. Figure 1A outlines the commitment and differen-
tiation of primitive hematopoietic and endothelial cells, in which
Flk1
+ mesoderm cells give rise to c-Kit
+, CD41
+ primitive
hematopoietic progenitors and also CD31
+, VEC
+ endothelial cells.
A small fraction of the Flk1
+, CD31
+,V E C
+ hemogenic endothelial
cells can also differentiate into hematopoietic cells [6,7,8]. Because
hematopoietic progenitor cells express Tie2, Flk1, and CD31
endothelial markers and c-Kit and CD41 hematopoietic markers,
we used fluorescence activated cell sorting of E9.5 embryonic cells,
and isolated Flk1 single positive cells as the hemangioblast
population, VEC
+ cells as endothelial cells, cKit
+, CD41
+ as
primitive hematopoietic progenitors, CD71
+ and Ter119
+ cells as
erythroblastic cells. Wild type E9.5 embryo or yolk sac cells were
pooled, and aliquots triple stained with fluorescent antibodies Flk1-
PE, c-Kit-APC and CD41-FlTC or CD71-APC, Ter119-PE, and
VEC-FITC and sorted. RT-qPCR of sorted cells showed a biphasic
expression pattern of Spry1, which is expressed in Flk1
+ progenitor
cells, but declines in c-Kit
+ and CD41
+ cells, and increases again in
Ter119
+ cells (Figure 1A, B). Spry2 is expressed in Flk1
+ progenitor
cells, and Spry2 expression parallels that of Spry1 until the Ter119
+
stage where its expression is down regulated. Spry4 is expressed in
Flk1
+ progenitors, butisdown regulatedduring subsequent stages of
hematopoietic development. In contrast, Spry1 and Spry2 expres-
sion levels in VEC
+ are similar to Flk-1
+ cells, but Spry4 expression
levels are lower. We also observed a strong increase in the
expression of FGFR2 in CD71
+ cells, which subsequently declined
inTer119
+cells.Thiscorrelateswell with previousobservationsthat
indicate that FGFR2 plays a role in hematopoiesis [12,23]. In vitro
differentiation of mouse ES cells using the hanging drop method
without LIF showed induction of Spry1 expression is biphasic, with
the first peak of expression occurring on day 4 of differentiation,
before the rise in Flk1 expression (Figure 1C). A second peak of
Spry1 expression occurs around day 11 when Flk1 expression has
peaked. Spry4 expression was relatively unchanged during ES cell
differentiation (data not shown).
Over expression of Spry1 in Tie2 expressing cells is
embryonic lethal
The Tie2 gene encodes an angiopoietin receptor, its expression
is detected as the first endothelial cell arise, and remains positive in
endothelial cells throughout development, and in all adult
endothelial cells [24,25]. Tie2 is not only expressed in adult and
embryonic ECs but in extra-embryonic Flk1
+ cells during
gastrulation, and in hematopoietic progenitor cells [26]. Tie2-Cre
transgenic mice have been extensively characterized [27,28] and
exhibit a similar expression pattern to Tie2-LacZ transgenic [29].
In addition, it was recently shown that the recombination
efficiency induced by Tie2-Cre transgenic mice was ,85% using
Rosa26R-EYFP and FACS analysis as the readout [30]. We
confirmed that Flk1
+ positive cells also express Tie2 in E7.5 and
E9.5 embryos by FACS (data not shown). To evaluate the role of
Spry1 in the development of hematopoietic and endothelial cell
lineages, we conditionally over-expressed Spry1 in Tie2-expressing
hemangioblastic cells using a Cre/LoxP strategy, which has been
described in detail elsewhere [31]. Crossing Tie2-Cre mice with
CAGGFP-Spry1 mice activated Spry1 expression; embryos that
genotype positive for both transgenes are called Spry1;Tie2-Cre.
Tie2-Cre mediated recombination was confirmed in extra
embryonic blood islands of E7.5 Spry1;Tie2-Cre;Rosa26LacZ
embryos by b-galactosidase staining (Figure 2A and data not
shown). This staining spread to all vascular components of the yolk
sac and embryo by E8.0. Spry1;Tie2-Cre transgenic embryonic yolk
sacs show a 2–8-fold increase in expression of Spry1 mRNA by
qPCR (Figure S1). Over-expression of Spry1 in Tie2-Cre
expressing cells resulted in an anemic phenotype (Figure 2B) and
embryos died between E10.5 and E11. Immunostaining of E9.5
yolk sacs with VEC antibodies showed a disruption in vascular
integrity and the formation of larger vessels in Spry1:Tie2-Cre
embryos but not in controls (Figure 2C, and l Figure S2).
Autofluorescent blood cells were scattered throughout the yolk sac
of Spry1;Tie2-Cre embryos, but were contained within larger vessels
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VEC
+ cells in Spry1;Tie2-Cre yolk sacs compared to controls,
although these cells were not organized into larger vessels
suggesting a defect in vascular remodeling or may reflect
hemangioblastic cells that are in transition to hematopoietic cells
but express residual VEC (Figure S2). b-galactosidase and isolectin
Grifonia simplicifolia (IB4) staining shows that at E9.5 the
vasculature has formed in Spry1;Tie2-Cre embryos, but the embryos
are smaller compared to controls (Figure 2D, and data not shown).
The reduced size of Spry1;Tie2-Cre embryos is likely a secondary
effect due to defects in hematopoiesis and anemia. Co-immuno-
staining with Flk1 and Myc antibodies showed that the Spry1
transgene was expressed albeit incompletely in Flk1
+ endocardial
cells lining the heart (Figure 2E). This immunostaining also
revealed that Spry1:Tie2-Cre embryos had a discontinuous Flk1
+
endocardium, whereas control embryos showed a continuous
Flk1
+ endocardium (Figure 2E).
Although b-galactosidase staining of E9.5 Spry1;Tie2-Cre embryos
showed apparently normal vasculature (Figure 2D), sections
through the heart showed a discontinuous endocardium
(Figure 2E). To determine whether other vascular defects were
present in Spry1;Tie2-Cre embryos, we stained transverse sections of
E9.5 embryos with Flk1, VEC and PECAM antibodies. Immuno-
fluorescent staining showed CD31
+, Flk1
+ and VEC
+ cells invading
Figure 1. Quantitative expression of Spry1, Spry2, and Spry4 during hematopoietic and endothelial cell development. (A) Schematic
illustration of endothelial and hematopoietic cell development. (B) RT-qPCR from sorted cells to show stage-dependent Sprys expression in
hematopoietic cell population and relative steady-state expression in endothelial cells. (C) RT-PCR to confirm the expression pattern of Spry1 in
hematopoietic cell development. (D) RT-qPCR of mRNA from differentiating embroid bodies to show the Spry1 expression pattern during ES cell
differentiation.
doi:10.1371/journal.pone.0018374.g001
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S3 and data not shown). In contrast, the neural tube of Spry1;Tie2-
Cre embryos was devoid of CD31
+ , Flk1
+ and VEC
+ cells indicating
a defectinvascular invasion oftheneural tube. Theseresults suggest
that endothelial cells form in the presence of over expressed Spry1
but that there are defects in vascular remodeling or secondary
developmental defects likely due to the anemia phenotype.
Over expression of Spry1 in Tie2-expressing cells impairs
primitive hematopoiesis but not endothelial cell
development
To further characterize the anemic phenotype of Spry1;Tie2-Cre
transgenic embryos, we analyzed the expression of hematopoietic
and endothelial marker genes by quantitative RT-PCR of E9.5
embryos or yolk sacs. The expression of genes associated with
hematopoietic development including Gata1, Runx1, and beta-
like embryonic hemoglobin chain 1 (ßH1) were significantly down
regulated in Spry1;Tie2-Cre yolk sacs and embryos compared to
controls. We also observed a down-regulation of Tie1, Tie2, Flt1,
Flk1, and VEC, but very little difference in the expression of
mesodermal marker Brachyury (Figure S4A and data not shown).
Although Tie2, Flk1 and VEC are markers of endothelial cells,
they are also expressed in hemangioblasts and transiently
expressed in intermediate progenitors during early hematopoietic
cell development [26,32]. To evaluate the defect in Spry1;Tie2-Cre
embryos at the cellular level, fluorescence-activated cell sorting
(FACS) was performed on E9.5 embryo and yolk sac cells and
shows that Tie2
+,CD41
+ or Flk1
+,CD41
+ hematopoietic progen-
Figure 2. Spry1;Tie2-Cre transgenic embryos exhibited an anemic phenotype and vascular defects. (A) The Rosa26LacZ reporter shows
efficient Tie2-Cre recombination and the pattern of transgene expression. (B) Spry1;Tie2-Cre (Spry1) transgenic embryos showed an anemic
phenotype, and a lack of large vessel development in the yolk sac compared to littermate controls (WT). (C) Whole mount immunostaining of
Spry1:Tie2-Cre (Spry1) yolk sacs at E9.5 with VEC antibodies shows a reduction in the formation of larger vessels compared to wild type controls (WT).
The unmerged images are shown in Supplemental figure 2. (D) Whole mount X-gal staining showed a relative normal vascular pattern in Spry1;Tie2-
Cre embryos compared to controls. (E) Flk1 and Myc co-immunostaining shows transgene expression of Spry1 in Flk1
+ cells, but reveals a
discontinued endocardium in Spry1;Tie2-Cre embryos compared to controls.
doi:10.1371/journal.pone.0018374.g002
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+ erythroblasts, and Ter119
+ erythroid cells are
significantly reduced in Spry1;Tie2-Cre embryos compared with
controls. However, the number of Tie2
+, CD41
2 and
Flk1
+,CD41
2 endothelial progenitor cells are increased relative
to the hematopoietic progenitor cells, although the total numbers
of Tie2
+,Flk1
+ or the numbers of Tie2
+,Flk1
+ cells are similar
between Spry1;Tie2-Cre embryos and controls (Figure 4A, B, C, D,
Figure S4 and data not shown). Because Tie2 expression begins at
E7.0 [26], Flk1
+ hemangioblastic cells, which also expressing Tie2,
lead to both hematopoietic and endothelial cells and are derived
from the mesoderm beginning at E7.5, we therefore examined
whether over-expression of Spry1 affects early Flk1
+ cell
differentiation. FACS analysis of E8.5 embryos showed the
number of Flk1
+ cells is similar between Spry1;Tie2-Cre embryos
and controls, however the number of CD41
+ cells is decreased in
Spry1;Tie2Cre embryos compared to controls (Figure S4F). Thus,
forced expression of Spry1 in Flk1
+ cells leads to a defect in the
commitment of these cells to the CD41
+ lineage.
To further evaluate the hematopoietic defects due to over-
expression of Spry1, we performed in vitro methylcellulose colony
forming assays on E9.5 AGMs or yolk sacs. Over expression of
Spry1 resulted in fewer erythroid and myeloid colonies compared
to controls (Figure 4E, F). Together these data suggest that forced
expression of Spry1 in Tie2-expressing cells impairs primitive
hematopoietic differentiation, but not endothelial cell develop-
ment.
Over expression of Spry1 in Tie2-expressing cells results
in a decrease in cell proliferation and increased apoptosis
in part through inhibition of ERK phosphorylation
One of the functions of Spry proteins is to inhibit RTK-
mediated ERK activation and subsequent cell proliferation and
survival in vitro. Therefore, it was of interest to determine whether
forced expression of Spry1 in Tie2 expressing cells in vivo had a
similar effect. Co-immunofluorescence staining was employed on
frozen sections of E9.5 embryos, and showed a significant
reduction of CD41
+ or CD71
+ and dpERK co-stained cells in
Spry1;Tie2-Cre embryos compared to controls (Figure 5A, C and
data not shown). Interestingly, we observed that most of the
intravascular CD41
+ and CD71
+ cells were not stained with
dpERK both in Spry1;Tie2-Cre or control embryos, and there were
only few VEC
+ stained cells that were dpERK positive (data not
shown). PCNA staining showed a reduction in proliferating cells in
Figure 3. Over-expression of Spry1 inhibits vascular invasion of the neural tube. (A) E9.5 embryo transverse sections were stained with
anti-CD31 antibodies followed by HRP-conjugated anti-rabbit antibody. The results showed a normal vascular plexus surrounding the neural tube in
both Spry1;Tie2-Cre (Spry1) and control embryos (WT), however the vascular plexus invaded the neural tube in wild type but not in Spry1;Tie2-Cre
transgenic embryos. (B) Quantification of CD31
+ cells in the neural tube of E10 embryos. CD31
+ cells were counted in the neural tubes of five sections
from at least 3 wild type and Spry1;Tie2-Cre embryos.
doi:10.1371/journal.pone.0018374.g003
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also noted that there were few CD41
+ or CD71+ and Myc-Spry1
co-stained cells, but most of VEC
+ stained cells were Myc-Spry1
positive in Spry1;Tie2-Cre embryos (data not shown). TUNEL
labeling showed a 2-fold increase in apoptosis in Spry1;Tie2-Cre
yolk sacs compared to control (Figure 5D, E). Together these data
indicate that over-expression of Spry1 in Tie2 expressing cells in
vivo inhibits hematopoietic cell proliferation and survival, and
increases apoptosis in part through inhibition of ERK activation.
While other pathways such as Akt may be involved, we could not
detect changes in Akt signaling by immunohistochemistry (data
not shown).
Figure 4. Over-expression of Spry1 in Tie2-expressing cells impairs formation of hematopoietic cells. (A) Representative FACS analysis
of E9.5 yolk sacs. (B) Quantification of FACS analysis on E9.5 yolk sacs show that over-expression of Spry1 significantly decreased CD41
+ primitive
hematopoietic progenitor, while the numbers of total Tie2
+ or Flk1
+ cells are not significantly affected. (C, D) Quantification of FACS analysis on E9.5
yolk sacs showed that over-expression of Spry1 significantly decreased Tie2
+,CD41
+ or Flk1
+,CD41
+ newly emerged hematopoietic progenitors, but
increased Tie2
+,CD41
2 or Flk1
+,CD41
2 hemangioblast and/or endothelial cells. (E, F) Colony forming assay on Methocult GF medium showed that
Spry1;Tie2-Cre transgenic embryo AGMs and yolk sacs formed far fewer hematopoietic colonies compared to controls.
doi:10.1371/journal.pone.0018374.g004
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+ and Ter119
+
cell populations
The hematopoietic defects in Spry1;Tie2-Cre transgenic mice
prompted us to evaluate whether loss of Spry1 function will
increase hematopoietic cell formation during embryogenesis.
Therefore, we analyzed hematopoietic cell populations from
E9.5 Spry12/2 embryos using FACS analysis. The results show
a dose-dependent increase of CD71
+ and Ter119
+ hematopoietic
cells in Spry1+/2 and Spry12/2 compared to Spry1+/+ E9.5
embryos (Figure 5F). The phenotypic penetrance is about 40%,
whereas the Flk1
+ cell population is comparable between Spry1+/+,
Spry1+/2 and Spry12/2 embryos. Therefore, down-regulation of
Spry1 favors the development and expansion of primitive
hematopoietic cells from hemangioblast precursors. Thus, normal
primitive hematopoietic development is sensitive to Spry1 levels.
Discussion
Spry inhibition of RTK-mediated ERK activation and
subsequent inhibition of cell proliferation, migration, and
differentiation has been documented in several cell types in vivo
and in vitro [33,34,35,36]. Morpholino oligonucleotide-mediated
knock down of Spry4 in zebrafish leads to hematopoietic defects,
however the mechanism is unclear [22]. The role of Sprys in
endothelial and hematopoietic development during mammalian
Figure 5. Forced expression of Spry1 impairs cell proliferation and survival in part through inhibiting ERK activation whereas
depletion of Spry1 leads to an increase in hematopoietic cell formation at E9.5. (A) Representative images of PCNA, dpERK, CD41 and Myc
immunofluorescence staining on E9.5 embryo sections (original magnification of 1006). (B) Quantification of percentage of PCNA
+ cells normalized
by total DAPI cells. (C) Quantification of percentage of dpERK
+ cells normalized by CD41
+ cells. (D) TUNEL staining of E9.5 yolk sac sections showed an
increase in TUNEL positive cells. (E) Quantification of TUNEL staining of D normalized to total DAPI
+ cells. (F) Quantification of FACS analysis on E9.5
yolk sacs showed an increase of CD71
+ and Ter119
+ cells in Spry12/2 and Spry1+/2 embryos compared to Spry1+/+ control embryos.
doi:10.1371/journal.pone.0018374.g005
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Spry1, Spry2, and Spry4 are expressed in Flk1
+ mesodermal cells
and their expression is maintained in VEC
+ endothelial cells, but
declines in c-Kit
+, CD41
+ hematopoietic cell lineages, suggesting
that Sprys may regulate the differentiation of the hematopoietic
and endothelial cell lineages differently. Indeed, Spry1;Tie2-Cre
transgenic embryos displayed significant reductions in CD41
+,
CD71
+ and Ter119
+ hematopoietic populations, whereas loss of
Spry1 results in increased CD41
+, CD71
+ and Ter119
+ hemato-
poietic populations in a gene dosage-dependent manner. Further-
more, we show that over-expression of Spry1 decreases CD41
+ or
CD71
+ cell proliferation and survival that correlated with a
decrease in ERK activation in these cell populations. However,
endothelial cell development and proliferation was relatively
unaffected in this context. Thus, our findings are of importance
not only for demonstrating the ERK signaling pathway is
important to hematopoietic cell expansion and survival, but also
for a better understanding of the role of Sprys in differentiation
and the subsequent expansion of hemangioblasts that lead to the
hematopoietic and endothelial lineages.
Hematopoietic differentiation and subsequent proliferation
from mesodermal stem cells are critical to the generation and
maintenance hematopoietic cell populations. Cytokines and
growth factors, such as FGF, VEGF-A, angiopoietin, c-Kit ligand,
BMPs and interleukins, have been shown to be important in
maintaining hematopoietic stem cell expansion and hematopoiesis
in vitro and in vivo [10], although the specific role of each signal
pathway remains unclear. Hematopoietic cytokines and growth
factors mediate cell proliferation in part through the ERK
pathway. ERK activation mediates proliferative effects through
downstream transcription factors including NF-kB, Ets-1, CREB,
AP-1, c-Myc and others. These transcription factors induce
expression of genes important for cell-cycle progression, such as
cyclins and CDKs, and Bcl-2, which promotes cell survival. Mice
lacking Mek1 display a reduction in CD4
+/CD8
+ thymocytes due
to a defective proliferation response of the T-cell receptor [37].
Loss of Gab2, an adaptor protein involved in PI3K and ERK
signal pathways, leads to defects in multi-lineage hematopoietic
cell expansion [38]. In this study, we demonstrate that a
proliferative hematopoietic defect in Spry1;Tie2-Cre transgenic
embryos is associated with significant decreases of CD41
+ or
CD71
+ and dpERK double positive cells, suggesting that ERK
activation is important for hematopoietic expansion during
embryogenesis.
Contradictory roles for FGFR signaling in the regulation of
hematopoiesis have been reported, with FGFR1 having a positive
effect, whereas FGFR2 negatively regulates hematopoiesis in
mouse and chick embryogenesis, respectively [11,12,23]. We have
shown a stage-dependent expression pattern of FGFR1 and
FGFR2 during hemangioblast differentiation into primitive
hematopoietic cells. Both FGFR1 and FGFR2 are highly
expressed in Flk1
+ hemangioblasts, and decline in cKit
+, CD41
+
primitive hematopoietic progenitors. Subsequently FGFR2 grad-
ually increases during further differentiation of hematopoietic cells,
while the peak expression of FGFR1 is in CD71
+ cells but
decreases in more differentiated Ter119
+ cells. This expression
pattern correlates well with the expression of Sprys, in agreement
with the concept that FGF/FGFR signaling regulates Sprys
expression. Our results suggest that: 1) FGF/FGFR signaling may
play a role in mesodermal Flk1
+ cell formation and expansion, 2)
down-regulation of FGF/FGFR signaling may favor the commit-
ment of Flk1
+ to the hematopoietic lineage, 3) FGFR1 may
promote the expansion of CD71
+ erythroblasts but may not be
required for further differentiation and maturation, and 4) FGFR2
may positively regulate erythrocyte differentiation and maturation.
Our results also suggest that the feedback circuit between FGFR
signaling and Sprys may be necessary for the hematopoietic
homeostasis. Further study is required for a better understanding
the role of FGF/FGFR signaling in the regulation of primitive
hematopoiesis.
The Tie2 receptor is expressed in mature endothelial cells,
endocardium and in the hemangioblast, a common precursor that
gives rise to hematopoietic and endothelial lineages. FACS analysis
of pooled normal E8.5 embryo and yolk sac cells showed about
10.3% of Tie2
+ cells co-expressing c-Kit, and 2.3% of Tie2
+ cells
co-expressing CD41 (Figure S5) confirming this concept. Howev-
er, the Myc-tagged Spry1 transgene in Spry1;Tie2-Cre embryos was
mainly detected in endothelial and endocardial cells, and only a
few CD41
+ cells had detectable Myc-tagged Spry1 transgene.
Rosa26LacZ reporter staining indicated that Tie2-Cre mediates
efficient recombination in our transgenic model. Therefore, it is
conceivable that over-expression of Spry1 impairs the survival or
viability of CD41
+ and CD71
+ cells. Indeed, a significant increase
in apoptosis occurred in hematopoietic cells of Spry1;Tie2-Cre mice
compared to controls.
Forced expression of Spry4 in endothelium inhibits endothelial
proliferation and vascular morphogenesis [20]. The importance of
Spry2 and Spry4 to vascular development was also shown in loss-
of-function studies where both genes were deleted [21]. Loss of
Spry1 leads to abnormal kidney development and is neonatal lethal
[39]. In this report, we did not observe a dramatic effect of Spry1
on endothelial cell development by gain- and loss- of function of
studies on E9.5 embryos, suggesting that Spry1 has little effect on
endothelial cell formation. However, because Spry1, Spry2, and
Spry4 are all expressed in Flk1
+ mesodermal cells and expressed in
VEC
+ cells, other Spry proteins may compensate for the effect of
changes in Spry1 expression on endothelial formation. Although
endothelial cell development in Spry1;Tie2-Cre embryos is normal,
and the number of VEC
+ cells in whole mount stained E9.5 yolk
sacs of Spry1;Tie2-Cre appears similar to or greater than wild type
controls, there is a failure of vascular remodeling in Spry1;Tie2 yolk
sacs as evidenced by a lack of larger vessels. Vascular integrity also
appears compromised in Spry1;Tie2-Cre yolk sacs because auto-
fluorescent blood cells were not contained with in vessels the way
they are in wild type control yolk sacs.
Hematopoietic cells derive from hemogenic endothelial cells,
which express Tie2, Flk1, VEC, and endoglin all markers of
endothelial cells [26] and expression of these endothelial marker
genes are decreased after hematopoietic commitment and
differentiation. By FACS analysis we also showed that newly
emerging hematopoietic cells (cKit
+ and CD41
+ cells) co-express
Tie2 and Flk1 both in wild type and Spry1;Tie2-Cre embryos and
yolk sacs. It is reasonable to expect that in wild type embryos
mature blood cells do not express endothelial markers, however in
Spry1;Tie2-Cre mice, over-expression of Spry1 may delay the down-
regulation of endothelial markers in committed hematopoietic cells
even after further differentiation. Further study is necessary to
address this phenomenon.
Although endothelial cell development seems unaffected by
over-expression of Spry1, we observed vascular defects including
discontinuous endocardium and failure of vascular invasion of the
neural tube in Spry1;Tie2-Cre transgenic embryos suggesting Spry1-
expressing endothelial cells have impaired functions in vivo.
Because Sprys inhibit branching morphogenesis in Drosophila and
mice [20,40], and vascular network formation of HUVEC on
Matrigel [41,42], it is possible that the vascular defects we
observed in Spry1;Tie2-Cre yolk sacs and embryos is due to Spry1
over expression directly, or alternatively this defect may be
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Other studies have shown that defects in hematopoiesis contribute
to vascular remodeling defects through changes in hemodynamic
forces and cytokine production [43,44]. To gain more insight into
the vascular defects associate with Spry expression, additional
studies using endothelial cell specific Cre-mediated gain- and loss-
of-function of Spry1 alone or in combination with other Spry
family members will be necessary to address this issue.
Materials and Methods
Ethics Statement
All experiments using mice were approved by the Maine
Medical Center Institutional Animal care and Use Committee and
conformed to the guidelines established in The Guide for the Use and
Care of Laboratory Animals.
Materials
Antibodies against Flk1 and VE-Cadherin were purchased from
Santa Cruz Biotechnology Inc. (Santa Cruz, CA). Phospho-
ERK1/2 and p-Akt antibodies were from Cell Signaling
Technology (Beverly, MA). Cy3-anti-Myc was from Sigma-
Aldrich Co. (St. Louis, MO). Phosphor-Histone 3 antibody was
from Millipore (Billerica, MA). FITC-anti-PCNA was from
Millipore. FITC-anti-CD41, FITC-anti-CD71, APC-CD71, Alexa
Fluor 488-anti-VEC, PE-anti-Tie2, PE-anti-Flk1, APC-Flk1, PE-
anti-Ter119, APC-anti-c-Kit and APC-anti-CD31 were purchased
from BD Biosciences (San Jose, CA). Alexa Fluor 488-anti-goat
IgG was from Invitrogen Corporation (Carlsbad, CA). Fluoresce-
in-conjugated anti-rabbit IgG, Fluorescein-anti-Mouse IgG were
from Vector Laboratories Inc. (Burlingame, CA). In Situ Cell
Death Detection kit TMR Red was purchased from Roche
(Indianapolis, IN). ProtoScript M-MuLV First Strand cDNA
Synthesis kit was purchased from New England Bio Labs (Ipswich,
MA). RT
2 Real-Time
TM SYBR Green/Fluorescein PCR Master
Mix was purchased from SABiosciences (Gaithersburg, MD).
Methocult GF medium was purchased from Stem Cell Technol-
ogies (Vancouver, BC, Canada).
Transgenic Mice
Spry1 gene targeted mice on an FVB background were from the
Mouse Mutant Regional Resource Center (UC, Davis). CAGGFP-
Spry1 transgenic mice on an FVB background were generated as
described previously [31]. Rosa26LacZ;Spry1 double transgenic
mice were obtained by breeding CAGGFP-Spry1 and Rosa26LacZ
mice (Jackson Laboratory). For evaluating the recombination
Rosa26LacZ or Rosa26LacZ;Spry1 female mice were bred with Tie2-
Cre male mice (Jackson Laboratory, B6.Cg-Tg(Tek-Cre)12Flv)
[27]. CAGGFP-Spry1 female mice were bred with Tie2-Cre male
mice to generate conditional transgenic mice. Embryos were
obtained from timed matings where first observation of the vaginal
plug was defined as E0.5. Mouse genotypes were confirmed by
PCR using genomic DNA extracted from tails or yolk sacs. Wild
type C57BL6 mice were used for Spry expression pattern profile
analysis. The Maine Medical Center Research Institute Animal
Care and Use Committee approved all procedures.
ES Cell culture
Mouse ES cells were maintained on mouse MEF feeder cells in
the presence of leukemia inhibitory factor (LIF) in DMEM
containing 15% Knockout
TM Serum replacement (Invitrogen).
Embroid body (EB) formation was performed using the hanging
drop method without LIF.
Fluorescence activated cell-sorting (FACS) analysis and
cell sorting
Embryos and yolk sacs from timed matings were digested in
0.5 ml 0.25% trypsin for 30 min at 37uC, digestion was stopped by
addition of 1 ml 10% FBS-DMEM and separated into a single cell
suspension through a 26-gauge needle. Cells were pelleted by
centrifugation at 1200 rpm for 5 min. Cell pellets were resus-
pended into 100 ul of 0.1% BSA-PBS buffer, blocked with normal
rat IgG (10 mg/ml) for 5 min at 4uC followed incubation for
30 min with fluorescent antibodies: PE-anti-Flk1, APC-anti-
CD31, FITC-anti-CD41, APC-anti-CD71, PE-anti-Ter119, Alex
Flor488-anti-CD144, PE-anti-Tie2. Co-stained cells were washed
with 0.1% BSA-PBS buffer, and filtered with MACS Pre-
Separation Filters (Miltenyi Biotec). Cells were analyzed on a
BD FACSCalibur
TM. Antibody labeled wild type cells were sorted
for Flk1
+, CD41
+, CD71
+, Ter119
+, c-Kit
+ and Flk1
+CD41
+ cell
populations on a BD FACSAria
TM. Student’s t-test was used for
statistical analysis.
RT-PCR and Quantitative real-time PCR
Total RNA was extracted from yolk sacs or embryos from timed
matings using RNeasy plus (Qiagen), or from sorted cell
populations using Micro RNeasy Plus (Qiagen). The purity and
concentration of RNA were measured with NanoDrop Spectro-
photometer (NanoDrop Technologies) at 260 nm/280 nm. The
ratios of 260 nm/280 nm of all samples were between 1.8 and 2.0.
ProtoScript M-MuLV First Strand cDNA Synthesis kit (New
England Biolabs) was used to generate cDNA. Quantitative real-
time PCR (qPCR) of target genes was performed using SYBR
Green (SABioscience) according to manufacture’s instructions on
an IQ5 Multicolor Real-Time PCR Detection System (BioRad).
GAPDH was used as an internal reference in each reaction.
Melting curve analyses using the program run in the step
acquisition mode was used to verify the presence of a single
amplification production. Primers for qPCR are shown in
supplementary Table S1. Student’s t-test was used for statistical
analysis.
Colony forming assays
Embryos at E9.5 were dissected out and the aorta-gonad-
mesonephros (AGMs) was isolated. Yolk sacs and AGMs were
digested with 0.25% trypsin for 20 min at 37uC, and passed
through a 26-gauge needle to obtain single cell suspensions. Cells
were pelleted by centrifugation at 1200 rpm for 5 min at 4uC. Cell
pellets were resuspended in 200 ml 10% FBS-DMEM and
counted. AGM cells or yolk sac cells were mixed individually
with 3 ml Methocult GF medium (Stem Cell Technologies) and
plated into two 3.5 cm dishes and cultured at 37uC. Colonies were
counted after 7 days based on morphology. At least 6 pairs of
Spry1;Tie2-Cre and wild type controls were used for analysis.
Student’s t-test was used for statistical analysis.
Histology and immunostaining
Embryos and yolk sacs were collected from timed pregnant
females after euthanasia according to IACUC protocol, fixed in
4% paraformaldehyde (PFA) for 2 hrs, washed with PBS and
saturated in sequential 15% and 30% sucrose solutions for 3 hours
each, and embedded in OCT. Embryos and yolk sacs were
sectioned at 6 mM. For whole mount X-gal staining, embryos were
fixed in 4% PFA for 15 minutes, washed with PBS twice and
stained in Ferri-F X-gal buffer. Co-immunostaining was per-
formed with two or more antibodies including anti-phospho-ERK,
anti-VEC, FITC-anti-CD41, FITC-anti-CD71, anti-pAkt, Cy3-
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detected by FITC-anti-PCNA or anti-phosphor-Histone 3 immu-
nostaining. Apoptosis was determined by TUNEL labeling using
the In Situ Cell Death Detection kit according to the manufac-
turer’s instructions. Nuclei were visualized with either TO-PRO
(Invitrogen), or 49,6-diamidino-2-phenylindole (DAPI), and sec-
tions were mounted using fluorescent mounting media. Images
were taken using a Zeiss Axioskop2 Plus fluorescence microscope.
For quantification of proliferation and apoptotic cells, at least 4
pairs of embryos or yolks of Spry1;Tie2-Cre and wild type controls
were sectioned and stained. At least 5 sections from each sample
were counted for quantification.
Data analysis
Results are presented as means 6 SEM. Statistical analysis of
differences between two groups was performed using the Student’s
t test. Statistical significance was determined at a value of P,0.05.
Supporting Information
Figure S1 Validation of Spry1 transgene expression by
RT-qPCR. Total RNA was extracted from E8.5 or E9.5 wild
type control or Spry1;Tie2-Cre embryos. RT-qPCR was per-
formed using mouse Spry1 and GAPDH primers. The relative
level was calculated by normalizing to GAPDH.
(DOC)
Figure S2 Failure of large vessel formation and matu-
ration in Spry1:Tie2-Cre yolk sacs. Whole mount staining of
E9.5 yolk sacs showed over-expression of Spry1 in Tie-2
expressing cells impaired yolk sac vascular remodeling and large
vessel formation. Yolk sacs from E9.5 wild type or Spry1;Tie2-Cre
mice were fixed in 4% PFA for 2 hours and immunostained with
VEC antibodies (green), autofluoresecent blood cells are indicated
in red. The nucleus was visualized with TO-PRO-3 iodide and
imaged using confocal microscopy. These images are representa-
tive of three independent experiments.
(DOC)
Figure S3 Failure of endothelial cell invasion into the
neural tube of Spry1;Tie2-Cre embryos. E9.5 embryos
were fixed in 4% PFA and sectioned at 5,7 mM. Sections were
stained with anti-Flk1 antibodies, followed by FITC-anti-rabbit
antibodies. Nuclei were visualized with DAPI. Red arrows indicate
Flk1
+ cells in the neural tube of WT embryos. (nt=neural tube,
cv=cardinal vein).
(DOC)
Figure S4 Over-expression of Spry1 in Tie2-expressing
cells impairs formation of hematopoietic cells. (A) RT-
qPCR of E9.5 Spry1;Tie2-Cre yolk sacs showed over-expression of
Spry1 decreased both hematopoietic and endothelial marker gene
expression. (B) Representative FACS analysis of E9.5 yolk sacs to
show over-expression of Spry1 impaired primitive erythropoiesis.
(C) Quantification of FACS analysis on E9.5 yolk sacs showed that
over-expression of Spry1 decreased CD71
+, Ter119
+ erythroid
and erythrocyte cells but not CD31
+ endothelial cells. (D)
Quantification of FACS assay on E8.5 embryo and yolk sac cells
showed a decreased CD41
+ hematopoietic progenitor cells but not
Flk1
+ and c-Kit
+ cells. (E) Representative of FACS analysis to
show over-expression of Spry1 decreases CD41
+ cells but not
Flk1
+ and c-Kit
+ cells at E9.5. Analyses were performed on E9.5
Spry1;Tie2-Cre and control embryos. (F) Representative of FACS
analysis to show over-expression of Spry1 decreases CD41
+ but
not Flk1
+ and c-Kit
+ cells at E8.5.
(DOC)
Figure S5 Hematopoietic cells originate from Tie2-
expressing endothelial cells. Pooled normal E8.5 embryo
and yolk sac cells were co-stained with PE-anti-Tie2, APC-anti-c-
Kit and FITC-anti-CD41 antibodies. FACS analysis showed that
c-Kit+ hematopoietic progenitors and CD41+ cells co-express
Tie2. Data are representative of three experiments.
(DOC)
Table S1 RT-qPCR Primers.
(DOC)
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